Compare Biogen Inc (BIIB) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Macy's Inc — how do they compare? Biogen Inc trades at $207.48 (market cap $30.13B), while Macy's Inc trades at $23.8 (market cap $6.45B). The key difference: Biogen Inc is far larger — about 4.7× Macy's Inc's market cap, and Macy's Inc pays a 3.12% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | M | |
|---|---|---|
Market Cap | $30.13B | $6.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $26.21 |
52-Week Low | $128.93 | $12.73 |
Enterprise Value | $37.20B | $10.26B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
Macy's stock trades at $23.78, down 4.5% over 24 hours, with technical indicators showing a bullish moving average signal but neutral oscillators. The company demonstrates improving fundamentals with three consecutive quarterly earnings beats and positive cash flow trends. Recent institutional buying and analyst coverage reflect cautious optimism amid the company's turnaround efforts.
The stock presents value investment potential with attractive valuation multiples (P/E 10.13, P/S 0.3) and improving profitability. Key risks include retail sector headwinds and execution of the 'Bold New Chapter' strategy. The consensus price target of $24.83 suggests modest upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
